

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal


Glofitamab with gemcitabine and oxaliplatin for treating relapsed or refractory diffuse large B-cell lymphoma [ID6202]

Final Stakeholder list

Provisional Consultees	Provisional Commentators (no right to submit or appeal)
Company	General
Roche Products (glofitamab)	All Wales Therapeutics and Toxicology Centre
Patient/carer groups	Allied Health Professionals Federation
African Caribbean Leukaemia Trust	Board of Community Health Councils in
Anthony Nolan	Wales
Black Health Agency for Equality	British National Formulary
Blood Cancer UK	Care Quality Commission
Cancer Black Care	 Department of Health – Northern Ireland
Cancer Equality	Healthcare Improvement Scotland
• Cancer52	Medicines and Healthcare products
DKMS	Regulatory Agency
Helen Rollason Cancer Charity	 National Association of Primary Care
 Independent Cancer Patients Voice 	National Pharmacy Association
Kevin Karawa Leukaemia Trust	NHS Confederation
Leukaemia Cancer Society	Scottish Medicines Consortium
Leukaemia Care	Welsh Government
Lymphoma Action	Welsh Health Specialised Services
Macmillan Cancer Support	Committee
Maggie's Centres	
Marie Curie	Comparator companies
South Asian Health Foundation	AbbVie (epcoritamab)
Specialised Healthcare Alliance	Accord Healthcare (bendamustine,
Tenovus Cancer Care	etoposide, gemcitabine, prednisolone,
WMUK	oxaliplatin)
VIVIOR	 Actavis (bendamustine, etoposide,
Healthcare professional groups	gemcitabine, prednisolone)
Association of Cancer Physicians	 Advanz Pharma (prednisolone)
British Geriatrics Society	Aspen (chlorambucil)
British Institute of Radiology	Baxter Healthcare (cyclophosphamide,
British Oncology Pharmacy	ifosfamide)
Association	 Bristol-Myers Squibb Pharmaceuticals
British Psychosocial Oncology Society	(etoposide)
British Society for Haematology	 Consilient Health (dexamethasone)
British Society of Interventional	 Dr Reddy's Laboratories UK

Final stakeholder list for evaluation of glofitamab with gemcitabine and oxaliplatin for treating relapsed or refractory diffuse large B-cell lymphoma [ID6202]

Issue date: November 2024




Provisional Consultees Provisional Commentators (no right to submit or appeal) Radiology (bendamustine) **British Transplantation Society** Eli Lilly and Company (gemcitabine) Cancer Research UK Hospira UK (gemcitabine, oxaliplatin) Kite, a Gilead company (axicabtagene NHS Blood and Transplant Royal College of General Practitioners ciloleucel) Medac UK (bendamustine, etoposide, Royal College of Nursing lomustine, oxaliplatin) Royal College of Pathologists Napp Pharmaceuticals (bendamustine, Royal College of Physicians rituximab) Royal College of Radiologists Pfizer (gemcitabine, vincristine) Royal Pharmaceutical Society Ranbaxy (UK), a Sun Pharmaceutical Royal Society of Medicine Company (gemcitabine) Society and College of Radiographers Roche (glofitamab, polatuzumab **UK Clinical Pharmacy Association** vedotin, rituximab) UK Cutaneous Lymphoma Group Sandoz (cyclophosphamide, rituximab) **UK Oncology Nursing Society** Seacross pharmaceuticals (bendamustine) Others Swedish Orphan Biovitrum Department of Health and Social Care (loncastuximab tesirine) **NHS** England Teva Nederland B.V. (bleomycin) Zentiva (bendamustine, prednisolone) Relevant research groups Cochrane Haematology Group Cochrane UK Genomics England Institute of Cancer Research Leukaemia Busters Leukaemia UK Lymphoma Research Trust MRC Clinical Trials Unit National Institute for Health Research Associated Public Health groups Public Health Wales UK Health Security Agency

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Final stakeholder list for evaluation of glofitamab with gemcitabine and oxaliplatin for treating relapsed or refractory diffuse large B-cell lymphoma [ID6202]

Issue date: November 2024



Definitions:

Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.